Medicines Australia Federal Budget 2020-2021 Infographic

Medicines Australia Federal Budget Submission 2020

Medicines Australia Federal Budget Submission 2019 2 pager

Medicines Australia Federal Budget Submission 2019

2018 – 2019 MA Federal Budget Submission

House of Representatives Standing Committee on Health, Aged Care and Sport inquiry into approval process for new drugs and novel medical technologies in Australia –  November 2020

Medicines Australia Summary of comments re: moving all existing and future Special Pricing Agreement deeds of agreement to monthly invoicing (June 2020)

Medicines Australia and members’ response to the proposed new policy on rescinding Pharmaceutical Benefits Advisory Committee positive recommendations (June 2020)

Medicines Australia’s submission to the final report of the Chronic Plaque Psoriasis Cost‐Effectiveness Review (June 2020)

Medicines Australia submission to the Draft Cost Recovery Implementation Statement (CRIS) for Listing Medicines on the PBS and Designated Vaccines on the NIP 1 July 2020 – 30 June 2021 (June 2020)

Medicines Australia Submission to TGA Scope of Regulated Software (May 2020)

Medicines Australia’s Response to Public Summary Documents (PSD) Process (April 2020)

Medicines Australia submission to the Draft Cost Recovery Implementation Statement (CRIS) for Listing Medicines on the PBS and Designated Vaccines on the NIP 1 July 2020 – 30 June 2021 (March 2020)

Medicines Australia OIT Cancer submission (March 2020)

Submission – Inquiry into supporting Australia’s exports and attracting investment

Submission – Inquiry into the implications of the COVID-19 pandemic for Australia’s foreign affairs, defence and trade

Submission – COVID-19 – Submission 233 

Medicines Australia submission to the Draft Cost Recovery Implementation Statement (CRIS) for Listing Medicines on the PBS and Designated Vaccines on the NIP 1 July 2020 – 30 June 2021

Medicines Australia Submission – Department of Health Lung Cancer Screening consultation

Submission – Treasury Laws Amendment (Research and Development Tax Incentive) Bill 2019

Consultation on adoption of European Union guidelines in Australia 

Medicines Australia submission on the TGA consultation on export of therapeutic goods from Australia

Medicines Australia submission to the Public Consultation – Revised Procedure Guidance – Resubmission Pathways

Medicines Australia submission to the Public Consultation – Revised Procedure Guidance – Initial Submission Categories and Single Submission Date

Medicines Australia submission to the Public Consultation – Revised Procedure Guidance – Public Summary Documents

Medicines Australia submission to the National Action Plan for Blood Cancer

Medicines Australia submission to the proposed changes to the medical device Essential Principles for safety and performance

Medicines Australia submission to the proposed clarification of the regulatory requirements for medical device systems and procedure packs

Medicines Australia submission to the Australian Government consultation on Data Sharing and Release – Legislative Reforms

Medicines Australia submission to the TGA consultation on modification of an existing provisional registration

Medicines Australia submission to the Inquiry into supporting Australia’s exports and attracting investment 

Medicines Australia submission to TGA consultation on increased online access to ingredient information

Medicines Australia submission to the TGA targeted consultation on generic medicines reforms 

Medicines Australia submission on the Public consultation on standardised redaction of Public Summary Documents

Medicines Australia submission to the Intellectual Property Laws Amendment (Productivity Commission Response Part 2 and Other Measures) Bill 2019 

Medicines Australia submission on the Extension of the Consultations for Sustainability Impact Assessment – Negotiations on FTA between the EU and Australia

Medicines Australia submission on the Department of Health Australia’s Antimicrobial Resistance Strategy 2020 and beyond 

Medicines Australia’s submission on the consultation paper specific to the introduction of a consumer-friendly Medicines Status Website (MSW)

Medicines Australia’s submission on the Public consultation on Positive Recommendation Pathways process and guidance

Medicines Australia’s submission to the Department of Health’s Review of the Quality Use of Medicines (QUM) Program Delivery by NPS MedicineWise 

Medicines Australia submission to the New Zealand Ministry of Health Therapeutic Products Regulatory Scheme – draft Therapeutic Products Bill

Medicines Australia’s submission to the Productivity Commission – The Social and Economic Benefits of Improving Mental Health

Medicines Australia’s submission to the consultation on whether the TGA should publish that a prescription medicine is under evaluation

Medicines Australia’s submission to the TGA Consultation on the reforms to the generic medicine market authorisation process

Medicines Australia’s submission to the Discussion Paper: Co-designing and publishing a Digital Medicines Program Blueprint 

Medicines Australia’s submission to the Australian Commission on Safety and Quality in Health Care’s Clinical Trials Governance Framework Consultation

Medicines Australia’s submission to the Consultations on PBS Process Improvements 

Medicines Australia’s submission to the TGA Consultation: Good Clinical Practice Inspections Program 

Medicines Australia response to the Draft Cost Recovery Impact Statement (CRIS) for Listing Medicines on the PBS and Designated Vaccines on the NIP 2019-20 

Medicines Australia response to the Therapeutic Goods Administration (TGA) consultations relevant to Medical Devices

Proposed criteria for Appendix M of the Poisons Standard to support rescheduling of substances from Schedule 4 (Prescription only) to Schedule 3 (Pharmacist only)

Therapeutic Goods Order 78 (TGO78) – Standard for tablets and capsules

Medicines Australia response to the Australian Government’s Vocational Education and Training (VET) review

Medicines Australia submission to provide input on the public consultation on the draft Intellectual Property (IP) regulations (December)

Medicines Australia – Consideration of proposed listing changes to antibiotic repeats on the Pharmaceutical Benefits Scheme  (December)

Medicines Australia response on the Therapeutic Goods Administration (TGA) consultation paper ‘Proposal for the regulation of IVD companion diagnostics’

Medicines Australia response to the Therapeutic Goods Administration (TGA) consultation paper ‘Transition to eCTD only for prescription medicines

Medicines Australia submission to the Joint Standing Committee on Trade and Investment Growth; Inquiry into Austrade’s role in attracting investment in Australia

Medicines Australia submission – Department of Foreign Affairs and Trade (DFAT) – Australia-European Union Free Trade Agreement (AEUFTA)

Medicines Australia response –  Consultation on the Community Service Obligation (CSO) Funding Pool Obligations (2019) 

Medicines Australia submission on the Therapeutic Goods Administration (TGA) consultation paper ‘Boxed Warning Guidance’ 

Medicines Australia submission – Senate Community Affairs References Committee – Inquiry into the My Health Record system

Medicines Australia response – World Health Organisation Global Patient Safety Challenge – Medication without harm (September)

Medicines Australia response to Science and Technology Australia – Medical Research Future Fund 2018-2020 Priorities Consultation (September)

Medicines Australia submission Pharmaceutical Society of Australia (PSA) 2023 Discussion Paper (September)

Medicines Australia submission to the consultation on the Intellectual Property Laws Amendment Bill 2018 (September)

Medicines Australia submission – PD-1 and PD-L1 checkpoint inhibitor immunotherapies: options for subsidy consideration for multiple cancer types (August)

Medicines Australia’s Response to the Consultation on the draft Treasury Laws Amendment (R&D) Bill 2018 (July)

TGA Consultation: Options for the implementation of a claimer for efficacy assessed non-prescription medicines (June)

Joint Standing Committee on Treaties Inquiry into the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (TPP-11)  (April)

Medicines Australia Consultation: Proposal to change the current good manufacturing practice (GMP) fees and charges (March)

Medicine’s Australia’s response to the TGA public consultation on the management and communication of medicines shortages (March)

Medicines Australia’s response to TGA’s Consultation paper on Prescription strong (Schedule 8) opioid use and misuse in Australia (March)

Submission to the Select Committee on Red Tape Inquiry into the effect of red tape on health services (January)

Medicines Australia submission to the public consultation on several Intellectual Property matters- Nov 2017  (November)

Medicines Australia Submission on the Secondary Use of My Health Record Data Public Consultation Paper 2017 (November)

Medicines Australia – response to Questions on Notice – Senate Select Committee into Funding for Research into Cancers with Low Survival Rates  (October)

Medicines Australia – Letter to Senate Select Committee relating to the Funding for Research into Cancers with Low Survival Rates (October)

Medicines Australia – response to TGA on proposed Schedule 3 Advertising Reforms and Advertising Code (October)

Medicines Australia – response to TGA Consultation Paper on Nomenclature of Biological Medicines (September)

Medicines Australia – cover letter to TGA Consultation Paper on Nomenclature of Biological Medicines (September)

MA Submission to the Review of Pharmacy Remuneration and Regulations Interim Report (July)

MA Submission to the Final Report of the Ezetimibe Post Market Review  (June)

Medicines Australia Submission to the Joint Committee Inquiry into Australia’s Trade and Investment Relationship with the United Kingdom (April)

MA submission to the Select Committee into Funding for Research into Cancers with Low Survival Rates, 31 March 2017 (31 March)

Submission to the Senate Committee Inquiry on the Therapeutic Goods Amendment Bill 2016  (17 March)

Medicines and Medical Devices Review – Response to TGA’s consultation paper on SAS B notifications and Authorised Prescribers Paper (February)

2017-18 Federal Budget Submission for The Innovative Medicines and Vaccines Industry (19 February)

Medicines Australia submission on PC Inquiry into IP Arrangements Final Report  (14 February)

Medicines Australia’s submission on the Draft Report of the Ezetimibe Post Market Review (10 February)

Submission to the 2017-18 Federal Government Budget (20 January)

Medicines and Medical Devices Review – Response to TGA’s consultation paper 2016 on Comparable Overseas Regulators  (19 December)

Medicines and Medical Devices Review – Response to TGA’s consultation paper 2016 on Expedited Pathways (19 December)

Response to TGA’s Consultation Paper on Orphan Drug Medicines (29 November)

Submission to the Senate Standing Committee on Foreign Affairs, Defence and Trade References Inquiry into the Trans-Pacific Partnership Agreement (3 November)

R&D Tax incentive Review Report Consultation 2016 (31 October)

Review of Pharmacy Remuneration and Regulation Discussion Paper (23 September)

Submission to Senate Inquiry into the Omnibus Bill 2016 (10 September)

Submission to the Productivity Commission Review of Intellectual Property Arrangements Draft Report (7 June)

Joint Submission to the Public Consultation on the Draft Terms of Reference for the Post-Market Review of Ezetimibe and Chronic Obstructive Pulmonary Disease (COPD) Medicines (22 April)

Submission to the Public Consultation on the draft chapter “Product Type 4 – Hybrid Technologies and Co-dependent Technologies” of the draft revised Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines (Draft Version 5.0) (11 April)

Submission to the Public Consultation on the draft revised Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines (Draft Version 5.0) (5 April)

Joint letter to the Review of the Research & Development Tax Incentive MA Submission (Mar 2016)

Submission to the 2016-17 Federal Government Budget (8 February)